CD86 and sarcoma: As shown in Figure 2, sunitinib treatment induced a significant upregulation of co-stimulation molecules CD80 and CD86 in both sarcoma cell lines (p < 0.01 and p < 0.0001, respectively) when compared to DCs loaded with untreated sarcoma cells.